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Certain properties and effect profiles are
thought to set endocrine-disrupting chemicals
(EDCs) apart from other hazardous substances.
Some EDC effects may be irreversible, such as
those resulting from interference with androgen
action during key steps of sexual differentiation
of males. Of concern with estrogens is their role
in breast and ovarian cancer [see recent review
by Kortenkamp (2006)]. Certain EDC-medi-
ated effects such as weight changes of sex acces-
sory glands have been shown to occur at dose
levels lower than those normally tested in toxi-
cology, often with unusually shaped dose–
response curves such as inverted Us. However,
these observations could not be replicated by
others [see the reviews by Ashby et al. (2004);
vom Saal and Hughes (2005); vom Saal et al.
(2005)], and this has provoked an unusually
heated controversy in the field, with claims
of bias due to sources of research funding
(vom Saal and Hughes 2005).
However, few systematic dose–response
studies have been carried out with EDCs, and
this has been highlighted as a deﬁciency by the
National Toxicology Program (NTP) Low-
Dose Peer Review Panel (NTP 2001). Most
EDC low-dose studies conducted to date have
employed only one or two different dose levels
and have used statistical hypothesis testing
procedures to compare the effects in treated
groups with those observed in controls. These
methods are commonly drawn on to derive no
observed effect levels (NOELs) but have been
sharply criticized by statisticians due to insufﬁ-
cient control for type II errors (Moore and
Caux 1997; Slob 1999). Type II errors occur
when experimenters arrive at the conclusion
that there is no effect when in fact there is one.
Increasingly, regression-based methods such as
the benchmark approach [Crump 2002; U.S.
Environmental Protection Agency (U.S. EPA)
1995] are promoted as alternatives to hypothe-
sis testing. One of the strengths of regression
methods lies in the fact that the statistical
power contained in the entirety of experimental
data is accessible for low-effect dose estimations.
This is not the case with hypothesis-testing
methods where the pair-wise comparisons
between controls and one dose group leave the
information available from other dose groups
unused. Regression analyses have rarely been
employed for the estimation of low effect doses
of EDCs. Systematic comparisons of low-dose
estimates derived from hypothesis testing with
those obtained by regression modeling are
missing for EDCs. 
We became interested in taking advan-
tage of the statistical power afforded by
high-throughput in vitro assays for low-dose
testing. Here, we present extensive dose–
response analyses with estrogenic agents in the
E-Screen assay. The E-Screen assay is an inte-
grative assay that exploits the principle that
MCF-7 human breast cancer cells proliferate in
the presence of chemicals that directly or indi-
rectly activate the estrogen receptor (Soto et al.
1995). Dose–response studies for 24 xenoestro-
gens including pesticides, ultraviolet (UV) ﬁlter
agents, cosmetics ingredients, industrial chemi-
cals, and phytoestrogens, as well as four
steroidal estrogens, were carried out with the
aim of evaluating whether there were unusually
shaped dose–response curves in the low-dose
range. A second aim of our studies was to arrive
at numeric estimates of low-dose effects of
estrogen-like chemicals. As a starting point for
realizing this aim, we have adopted a deﬁnition
of “low dose” in the sense of “low-effect doses,”
that is, doses associated with small responses.
Thus, it became necessary to deﬁne the sensi-
tivity of the E-Screen in detecting small effects.
We have approached this task by comparing
NOELs with point estimates of low effects
obtained from regression-based approaches.
This opened the way for taking account of an
alternative deﬁnition of “low dose” in terms of
“doses similar to exposure levels experienced by
humans” (NTP 2001) by comparing the low-
effect dose estimates for these 24 xenoestrogens
with information about the levels of these
substances in human tissues.
Materials and Methods
Chemicals. 17β-Estradiol (E2; 99% purity),
estrone (99%), estriol (98%), dienestrol
(98%), hexestrol (98%), aldrin (98.6%),
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BACKGROUND: Certain effects induced by endocrine-disrupting chemicals (EDCs) may occur at
dose levels lower than those normally tested in toxicology, but few systematic dose–response studies
have been carried out in the low-dose range.
OBJECTIVES: The high statistical power afforded by a high-throughput in vitro assay such as the
E-Screen assay was exploited with the aim of producing low-dose estimates for 24 estrogenic chemi-
cals, including endogenous hormones and xenoestrogens. 
RESULTS: Unusual dose–response curves with inverted U-shapes were not observed in the low-dose
range. Instead, many chemicals exhibited curves with very small gradients at low doses, and this
complicated the reliable estimation of low effects. Systematic comparisons between the outcomes of
hypothesis-testing procedures (lowest observed effect concentrations—LOECs, no observed effect
concentrations—NOECs) and regression modeling approaches (EC01—effective concentration caus-
ing a 1% effect, EC05—effective concentration causing a 5% effect) produced estimates that agreed
reasonably well. In many cases, NOECs were shown to be associated with proliferative responses of
1–2%. This is in contrast with the widespread perception of NOECs as values that signal complete
absence of effects. For many of the tested xenoestrogens, the NOECs, EC01, and EC05 were in the
nanomolar range, and comparisons with measured serum and adipose tissue levels in Europe
revealed considerable overlaps in some cases. 
CONCLUSIONS: Our studies illustrate the difﬁculties that may be encountered during the estimation
of low doses in vivo. High statistical power is required when the underlying dose–response curves
are shallow. Through the use of large sample sizes and numerous repeats, the experimental power
of the E-Screen assay was sufﬁciently high to measure effect magnitudes of around 1–2% with relia-
bility. However, such resources are usually not available for in vivo testing, with the consequence
that the statistical detection limits are considerably higher. If this coincides with shallow
dose–response curves in the low-effect range (which is normally not measurable in vivo), the
limited resolving power of in vivo assays may seriously constrain low-dose testing. 
KEY WORDS: endocrine disruption, exposure assessment, low dose, NOEC, regression modeling.
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http://dx.doi.org/ [Online 8 June 2007]dieldrin (99.8%), α-endosulfan (I; 99.5%),
β-endosulfan (II; 99.2%), methoxychlor
(99.5%), kepone (99%), 1,1,1-trichloro-2-
(o-chlorophenyl)-2-(p-chlorophenyl)-ethane
(o,p´-DDT; 97.5%),o,p'-dichlorodiphenyl-
dichloroethane (o,p´-DDD; 99%), 1,1,1-
trichloro-2,2-bis(p-chlorophenyl)-ethane
(p,p´-DDT; 99.1%), 1,1-dichloro-2,2-bis(p-
chlorophenyl)-ethylene (p,p´-DDE; 99.5%),
β-hexachlorocyclohexane (HCH; 98.1%),
coumesterol (98%) butyl paraben, propyl
paraben, and bisphenol A (> 99%) were pur-
chased from Sigma-Aldrich Co. (Dorset,
UK). 3-(4-Methylbenzylidene)camphor
(4-MBC, Eusolex 6300; > 99.7%) and octyl-
methoxycinnamate (OMC, Eusolex 2292;
> 98%) were from VWR International, LLC
(Poole, UK). 3-Benzylidene camphor (3-BC,
Unisol-22, > 97%) was from Induchem
(Volketswil, Switzerland). Genistein was
obtained from Alfa Aesar (Lancashire, UK).
All chemicals were used as supplied and
stock solutions (1–10 mM) were prepared in
high-performance liquid chromatography–
grade ethanol (VWR International). Stock
solutions and subsequent dilutions were
stored at –20°C. All remaining chemicals
were purchased from Sigma-Aldrich unless
stated otherwise.
Routine cell culture. MCF-7 BOS breast
cancer cells were kindly provided by Ana Soto
(Tufts University, Boston, MA, USA) and rou-
tinely maintained in 75 cm2 canted-neck tissue
culture ﬂasks (Greiner, Gloucestershire, UK) in
Dulbecco’s modiﬁed Eagle’s medium (DMEM;
Invitrogen Corp., Paisley, UK) supplemented
with 5% fetal bovine serum (FBS; Invitrogen)
and 1% (vol/vol) MEM–nonessential amino
acids (MEM-NEAA, Invitrogen) in a humidi-
fied incubator at 37°C with 5% CO2. Cells
were subcultured at approximately 70% conﬂu-
ence over a maximum of 10 passages and regu-
larly tested negative for Mycoplasma.
The E-Screen assay. The protocol described
previously (Rajapakse et al. 2004; Soto et al.
1995) was adopted to a miniaturized format
using 96-well microtiter plates. MCF-7 BOS
were seeded into the central 48 wells of 96-well
plates (Falcon; BD Biosciences, Oxford, UK) at
a density of 2,500 cells per well in a volume of
200 µL and allowed to attach for 24 ± 2 hr.
Peripheral wells on the microtiter plate were
ﬁlled with sterile water. 
The media change into experimental con-
ditions was carried out on a plate-by-plate
basis and with two lanes at a time. This was to
control and minimize the time the cells were
left in rinse media, without FBS. We found
that cells kept for too long without seeding
medium grew suboptimally, and this intro-
duced errors leading to poor reproducibility.
The seeding media of the top two lanes
was gently aspirated and the attached cells
rinsed with 200 µL phenol red–free DMEM
(Invitrogen). The rinse medium was then
replaced with 200 µL experimental medium
[charcoal–dextran (CD)-DMEM] consisting
of phenol-red free DMEM supplemented with
1% (v/v) sodium pyruvate, 1% MEM-NEAA,
and 10% CD-stripped FBS, with the appro-
priate concentration of the test compound.
These top two rows contained eight increasing
concentrations of the test chemical solubilized
in ethanol (ﬁnal ethanol concentration: 0.5%)
and tested in duplicate. The next row, as well
as one row between positive and negative con-
trols, was left untreated to avoid ”creeping” of
the test chemical to adjacent wells. The
remaining two rows were treated in the same
way as the ﬁrst two. One contained negative
controls (CD-DMEM + 0.5% ethanol in
8 wells) and the other positive controls
[CD-DMEM + E2 (20 nM) in 8 wells]. 
To minimize the number of cells being
lost from the bottom of the wells during
media changes, rinsing, and treatment, all
pipetting was carried out using a low-ejection
force electronic multichannel pipettor, and
great care was taken to avoid long direct con-
tact of the pipettor tip with the bottom of the
well, as this would have dislodged cells.
After 120 hr, the assay was terminated by
placing the plates on ice for 1 min before gen-
tly removing the experimental media and
replacing it with 200 µL ice-cold 10%
(wt/vol) trichloroacetic acid, 10% (wt/vol).
The plates were left on ice for 25 min, then
rinsed gently 5 times with water and allowed
to air dry. Cells were then stained with 0.4%
sulforhodamine B (SRB) in 1% (vol/vol)
acetic acid for 10 min. The bound dye was
solubilized with 100 µL Tris-base and the
optical density (OD) read at 510 nm directly
in the same plate on a microplate reader
(Labsystems Multiskan; VWR International,
Ltd., Leicestershire, UK). It had been estab-
lished previously that there is a direct linear
relationship between cell number to OD val-
ues of the Tris–SRB solution and experimen-
tal readings were in the linear range of the
standard curve (data not shown).
To reduce intraexperimental variability,
data were normalized on a plate-by-plate basis.
Data were scaled between 0 (ethanol controls)
and 1 (positive controls). A detailed description
of the data normalization procedure has been
published previously (Rajapakse et al. 2004).
All compounds were tested in at least four
independent experiments run on up to three
plates, with each plate containing eight increas-
ing concentrations of the test chemical in
duplicates. Hexestrol, dienestrol, 4-MBC, and
OMC were tested twice on two plates each.
Statistical analysis and regression model-
ing. Statistical dose–response regression analy-
ses were carried out by applying a best-fit
approach (Scholze et al. 2001). Various non-
linear regression models (logit, probit
Weibull, generalized logits I and II), which all
describe monotonic sigmoidal dose–response
relationships, were ﬁtted independently to the
same data set, and the best-ﬁtting model was
selected on the basis of a statistical goodness-
of-fit criterion, the information criterion of
Schwarz (Schwarz 1978). High-dose ranges
for which the effect data showed a down-turn
trend (U-shape) were excluded from data
analysis. Results are shown in Table 1. 
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Table 1. Best-ﬁt dose–response regression models for single agents.
Dose–response model
Agent RMa θ ˆ
1 θ ˆ
2 θ ˆ
3 θ ˆ
max
E2 Glogit I 4.5096 2.7536 0.45 1.0564
Estrone Glogit I 0.4974 2.5925 0.8 1.1166
Estriol Logit 1.6755 2.095 — 1.0466
Dienestrol Logit 1.4429 2.1938 — 0.9869
Hexestrol Logit 3.2681 2.3778 — 1.0456
Aldrin Glogit I –27.8067 6.758 0.4 0.2017
Dieldrin Weibull –12.161 3.4927 — 0.2749
α-Endosulfan (I) Weibull –8.3585 2.3992 — 0.7868
β-Endosulfan (II) Weibull –10.9876 3.2219 — 0.6104
Methoxychlor Glogit I –16.3428 4.7194 0.6 0.502
Kepone Logit –10.7149 3.4871 — 0.8707
β-HCH Weibull –10.5131 3.1265 — 0.851
o,p´-DDT Weibull –6.6162 2.3712 — 0.774
o,p´-DDD Glogit I –15.0151 4.5633 0.8 0.6798
p,p´-DDT Glogit I –17.2676 4.6968 0.7 0.4967
p,p´-DDE Glogit I –13.5761 4.0539 4.1 0.4083
Coumesterol Probit –1.9078 1.2555 — 0.984
Genistein Logit –6.5572 3.2505 — 0.8407
Bisphenol A Logit –7.2311 2.7223 — 0.9243
Butyl paraben Logit –8.7661 2.5275 — 0.8803
Propyl paraben Logit –12.5415 3.6135 — 0.8589
3-BC (Unisol S-22) Probit –6.6218 2.0243 — 0.7271
OMC (Eusolex 2292) Glogit I –4.3049 1.6947 6.4 0.2939
4-MBC (Eusolex 6300) Weibull –10.1145 2.7876 — 0.4224
aRM, regression models as deﬁned by Scholze et al. (2001); for more details see “Material and Methods.” θ ˆ
1, θ ˆ
2, θ ˆ
3: statisti-
cal estimates of model parameters, given for doses expressed as nM (rounded values); θ ˆ
max: upper model asymptote.Data analysis was always performed on
pooled data from all the repeat studies. To
account for the intra- and interstudy variabil-
ity associated with this nested data scenario,
the generalized nonlinear mixed modeling
approach was used, in which both fixed and
random effects are permitted to have a non-
linear relationship with the effect end point
(Vonesh and Chinchilli 1996). As potential
sources for random effects, two cases were
identified for the normalized end point:
dose–response data from different studies var-
ied in their curve steepness, which was dealt
with by including an additional random effect
to the steepness model parameter, and slight
shifts of the whole curves based on the log10-
transformed concentration scale were
observed, which was accounted for by includ-
ing an additional shift parameter as random
effect in the nonlinear regression model. The
random effects were assumed to follow a
Gaussian distribution with an expectation of
zero and thus were not included in Table 1.
The effect concentrations shown in Table 2
were selected for three low-response levels (10,
5, and 1% normalized cell proliferation) and
were calculated from the functional inverse of
the best-ﬁtting model. Statistical uncertainties
for the estimated effect doses were expressed as
95% conﬁdence belts and approximately deter-
mined by applying the bootstrap method
(Efron and Tibshirani 1993).
NOEC and lowest observed effect concen-
tration (LOEC) values were derived by testing
a trend in concentration effects against control
by using nonparametric multiple contrast tests
(Neuhaeuser et al. 2000). This method is con-
sidered a very powerful and robust test [see
Neuhaueser et al. (2000) for more details].
Results
During our studies with the E-Screen assay, we
encountered three prototypical dose–response
relationships, characterized by speciﬁc features
of shape, gradient, and position (Figure 1). As
an example for a typical steroidal estrogen,
estriol exhibited the full range of effects, pro-
ducing the maximal proliferative response
observed with E2, which was routinely used as
a positive control. With a median effect con-
centration of 0.1 nM, its potency fell in the
range of other steroidal estrogens. The phyto-
estrogen coumesterol was about 100 times less
potent than estriol and provoked only 90% of
the maximal effect. At the highest tested con-
centrations, there was a noticeable down-turn
in responses, giving rise to an inverted
U-shape. This phenomenon became much
more pronounced with the pesticide β-endo-
sulfan, which produced a maximal effect of
only 70%, followed by a decline of the
response with rising concentrations of the pes-
ticide. Because of the nature of the E-Screen
assay, it is not possible to delineate whether
this reduction in response is the result of cell
toxicity or cell proliferation arrest. As is typical
for the E-Screen, data variation increased with
effect magnitude and was lowest around nega-
tive control responses. Toward the lower range
of responses, the curves for estriol and coumes-
terol were slightly shallower than the curve for
β-endosulfan. The best-ﬁtting regression mod-
els used for these three agents are shown in
Table 1 together with those employed for all
other tested chemicals.
Application of hypothesis testing proce-
dures (nonparametric multiple contrast test)
allowed us to estimate LOECs (Table 2), and
these were 4.0 × 10–4 nM, 0.55 nM, and
410 nM for estriol, coumesterol, and β-endo-
sulfan, respectively. Consequently, the next
lower tested concentrations could be desig-
nated as NOEC values (depicted as blue cir-
cles in Figure 1), and these were 3.6 ×
10–4 nM for estriol, 0.24 nM for coumesterol,
and 150 nM for β-endosulfan. Regression
analysis yielded low-dose estimates that dif-
fered slightly from the NOECs (Table 2). For
β-endosulfan, the concentration estimated to
produce a 1% effect (EC01) was lower than
the NOEC (140 nM vs. 150 nM for β-endo-
sulfan). The EC01 values for coumesterol
(0.47 nM) and estriol (9.7 × 10–4 nM) were
higher than the NOECs for these chemicals.
By far the most extensive low-dose studies
were carried out with E2 and the chlorinated
hydrocarbon β-HCH, a waste product of lin-
dane production. For reasons that remain to be
clarified fully, we encountered considerable
response variations with E2. Curiously, this was
restricted to doses corresponding to low effects
but did not extend to the median-effect range.
Comparable response variations also did not
occur with the other tested steroidal estrogens
(estrone, estriol, dienestrol, hexestrol). Figure 2
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Table 2. Estrogenicity of single agents (all concentrations in nM, agents sorted by their EC10).
No. No.  EC10/ LOEC/ LOEC/
Agent studies platesa NOEC LOEC EC10 EC05 95% CI EC01 95% CI EC01 EC05 EC01
E2
b 32 1–2 cc 2.9E–04 8.0E–05 (2.8E–05; 1.6E–04) 4.0E–06 (6.9E–07; 1.3E–05) 72.5 — —
Hexestrol 2 2 ND 9.1E–06 4.8E–03 2.3E–03 (1.5E–03; 3.2E–03) 4.7E–04 (2.3E–04; 8.5E–04) 10.2 < 0.01 0.02
Estriol 10 2 3.6E–04 4.0E–04 1.3E–02 5.9E–03 (3.6E–03; 9.5E–03) 9.7E–04 (4.4E–04; 2.1E–03) 13.9 0.07 0.41
Dienestrol 2 2 8.7E–04 3.3E–03 2.2E–02 1.0E–02 (6.0E–03; 1.8E–02) 1.8E–03 (7.0E–04; 4.7E–03) 12.4 0.33 1.85
Estrone 10 2 6.6E–05 3.6E–04 4.6E–02 2.1E–02 (1.6E–02; 3.0E–02) 3.4E–03 (2.2E–03; 6.2E–03) 13.4 0.02 0.11
Coumesterol 4 1–3 2.4E–01 5.5E–01 3.2E + 00 1.6E + 00 (1.1E + 00; 2.8E + 00) 4.7E–01 (2.4E–01; 9.7E–01) 6.8 0.33 1.17
Genistein 5 1 2.3E + 00 9.2E + 00 2.5E + 01 1.5E + 01 (1.0E + 01; 3.0E + 01) 4.5E + 00 (2.6E + 00; 1.3E + 01) 5.5 0.62 2.02
Bisphenol A 4 1 5.3E + 00 1.7E + 01 7.6E + 01 4.0E + 01 (2.8E + 01; 5.8E + 01) 9.9E + 00 (5.2E + 00; 1.8E + 01) 7.7 0.41 1.66
o,p´-DDT 6 1 1.9E + 01 5.2E + 01 9.0E + 01 4.5E + 01 (2.7E + 01; 8.8E + 01) 9.1E + 00 (3.4E + 00; 2.8E + 01) 9.9 1.16 5.67
Kepone 5 1 9.7E + 01 2.1E + 02 3.1E + 02 1.9E + 02 (1.3E + 02; 3.0E + 02) 6.2E + 01 (3.1E + 01; 1.4E + 02) 4.9 1.15 3.41
Butyl paraben 4 1–2 3.3E + 01 1.0E + 02 4.3E + 02 2.2E + 02 (1.6E + 02; 3.2E + 02) 5.0E + 01 (3.2E + 01; 8.3E + 01) 8.6 0.47 2.09
α-Endosulfan (I) 5 1 9.0E + 01 2.3E + 02 4.5E + 02 2.2E + 02 (1.3E + 02; 3.8E + 02) 4.7E + 01 (1.8E + 01; 1.0E + 02) 9.7 1.05 5.05
β-HCHd 10 1–2 5.2E + 01 7.4E + 01 5.0E + 02 2.9E + 02 (2.0E + 02; 3.7E + 02) 8.8E + 01 (5.0E + 01; 1.3E + 02) 5.7 0.25 0.85
3-BC (Unisol S-22) 5 2 1.7E + 02 4.8E + 02 5.4E + 02 3.4E + 02 (2.7E + 02; 4.8E + 02) 1.5E + 02 (1.0E + 02; 2.6E + 02) 3.5 1.39 3.16
o,p´-DDD 4 2 8.2E + 01 2.0E + 02 6.1E + 02 3.8E + 02 (2.7E + 02; 6.1E + 02) 1.4E + 02 (7.3E + 01; 3.0E + 02) 4.5 0.53 1.50
β-Endosulfan (II) 10 1–2 1.5E + 02 4.1E + 02 7.5E + 02 4.4E + 02 (3.3E + 02; 6.0E + 02) 1.4E + 02 (8.3E + 01; 2.3E + 02) 5.5 0.92 2.96
Methoxychlor 6 1 8.2E + 01 2.0E + 02 8.1E + 02 4.5E + 02 (2.6E + 02; 7.9E + 02) 1.2E + 02 (3.6E + 01; 3.1E + 02) 6.7 0.46 1.71
Propyl paraben 3 1 1.0E + 02 3.3E + 02 8.1E + 02 5.0E + 02 (4.1E + 02; 5.7E + 02) 1.7E + 02 (1.3E + 02; 2.2E + 02) 4.7 0.66 1.91
4-MBC (Eusolex 6300) 2 2 ND 2.3E + 01 1.4E + 03 7.7E + 02 (6.5E + 02; 1.3E + 03) 1.9E + 02 (1.4E + 02; 4.3E + 02) 7.4 0.03 0.12
p,p´-DDT 4 2 7.8E + 01 8.2E + 01 1.6E + 03 9.7E + 02 (6.6E + 02; 1.3E + 03) 3.1E + 02 (1.4E + 02; 5.1E + 02) 5.3 0.08 0.27
Dieldrin 7 1 6.8E + 02 1.7E + 03 1.8E + 03 1.1E + 03 (6.4E + 02; 1.7E + 03) 3.5E + 02 (1.4E + 02; 9.5E + 02) 5.2 1.58 4.82
OMC (Eusolex 2292) 2 2 5.7E + 02 1.6E + 03 3.5E + 03 1.6E + 03 (9.3E + 02; 4.4E + 03) 5.7E + 02 (2.8E + 02; 3.1E + 03) 6.1 1.00 2.89
p,p´-DDE 4 1 1.5E + 03 3.2E + 03 3.7E + 03 2.8E + 03 (2.3E + 03; 4.0E + 03) 1.8E + 03 (1.0E + 03; 3.1E + 03) 2.1 1.15 1.80
Aldrin 4 2 2.1E + 03 3.8E + 03 7.6E + 03 4.0E + 03 (3.1E + 03; 5.9E + 03) 1.0E + 03 (5.3E + 02; 2.2E + 03) 7.6 0.94 3.75
Abbreviations: EC10, EC05, EC01, effect concentrations for 10, 5, and 1% cell proliferation in relation to control and maximal responses, derived from regression modeling (rounded values);
ND, not determined, i.e., effect for lowest tested concentration showed is signiﬁcant (LOEC); NOEC/LOEC, no/lowest observed effect concentrations (nM), determined by nonparametric
contrast test; 95% CI, 95% conﬁdence intervals for effect concentrations.
aEach plate contains eight concentrations tested in duplicate. bBased on pooled data from all studies. cDetermined values varied between studies: 1.6E–7 – 6.4E–5 LOEC; dBased on all
data shown in Figure 2, namely, data from the EC01 conﬁrmation study is not included.compares the outcome of dose–response stud-
ies carried out in 2004 (gray circles) with those
obtained from more recent experiments where
different E2 stock solutions were used.
Although the variations in the median-effect
range were relatively low, even among studies,
the proliferative response induced by the hor-
mone varied strongly at effect levels below 0.3.
In this low-effect range, two repeat studies car-
ried out with a dilution series prepared from
the same stock solution (black and light blue
circles in Figure 2) yielded higher responses
than those in an experiment conducted with a
different E2 stock solution (dark blue circles),
which in turn agreed very well with the histori-
cal data set (gray circles). Because of the low
gradient of the dose–response curves, the EC05
(concentration estimated to produce a 5%
effect) estimates for E2 that can be derived
from these studies cover the range between 3 ×
10–6 nM and 2.2 × 10–4 nM. Regression
analysis of the pool of all data gave an EC05 of
8 × 10–5 nM and an EC01 of 4 × 10–6 nM.
Because of the shallow gradient of the
dose–response curve in this low-effect range,
the 95% confidence intervals (CIs) for these
effect concentrations were very large (Table 2).
The variability associated with different stock
solutions of E2 was only observed for low con-
centrations of the hormone and was not
observed for any of the other tested com-
pounds. This rules out the possibility of experi-
mental errors during the preparation of stock
solutions and subsequent dilutions.
In contrast to our studies with E2, the
experiments carried out with β-HCH proved to
be very reproducible. Regression analysis of an
initial low-dose study produced an EC1 esti-
mate of 40.2 nM (black open circles in
Figure 2). In a second experiment, we decided
to assess the validity of this low-dose estimate
by using a hypothesis-testing approach where
the 40 nM concentration was retested with a
large number of replicates and compared with
control readings without further dose–
response analysis. This study confirmed the
original EC01 estimate, with a statistically sig-
niﬁcant proliferative effect of 1.22% and a 95%
CI of 0.06–1.8% (n = 16, p = 0.007, t-test; data
not shown in Figure 2). In an attempt to probe
the predictive value of this estimate by regres-
sion analysis, multiple concentrations of
β-HCH between 1 and 100 nM were retested
with a high and equal number of replicates and
controls (light blue open circles in Figure 2).
The outcome of this third study was in good
agreement with those of the initial experiment.
Regression analysis of the pooled data set from
all three experiments gave a revised EC01 esti-
mate of 88 nM, and an NOEC of 52 nM.
The remaining xenoestrogens gave results
that were generally very reproducible. Their
low-dose estimates, including EC10 (concen-
tration estimated to produce a 10% effect),
EC05, EC01, LOEC, and NOEC, are listed in
Table 2. For most compounds, the LOECs—
estimates derived from hypothesis testing pro-
cedures—were equivalent to effects of between
1 and 5% and in five cases even below 1%
(hexestrol, estrone, β-HCH, 4-MBC, and
p,p´-DDT). NOECs often equated to
responses of around 1%; in four cases (estriol,
estrone, propyl paraben, p,p´-DDT) they were
even signiﬁcantly below the EC01 (i.e., outside
the corresponding 95% conﬁdence belt). 
Judged by their high EC10/EC01 ratios,
some chemicals exhibited extremely shallow
dose–response curves in the low-effect range.
E2 represents the most extreme case, with a
ratio of 72.5. Many of the steroidal estrogens
also produced rather shallow curves, a charac-
teristic not observed with many of the syn-
thetic xenoestrogens. Small gradients may
increase the uncertainty associated with low
dose estimates, as reflected by the larger CIs
for the respective effect concentrations
(Table 2).
The often surprisingly small numeric values
of the low-dose estimates for the tested agents
prompted us to relate these readings (NOEC,
EC01, and EC05) to the range of levels found in
human tissues. Where available for the tested
chemicals, concentrations in serum and in
adipose tissue measured in European countries
were chosen as comparators (Figure 3). The ref-
erence studies used in the preparation of
Figure 3 are listed in Table 3. It includes only
those that reported the highest and lowest con-
centrations of the contaminants in either tissue.
A large number of other publications from sev-
eral European countries, including Belgium,
Denmark, Germany, and Holland, were also
analyzed. They all reported levels between the
extremes presented in Table 3 (Dallinga et al.
Silva et al.
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Figure 2. Concentration–response data and curves for E2 (circles) and β-HCH (open circles). Colors pre-
sent data from different independent studies: same stock solution (black and light blue) or different stock
solution (dark blue), or data from 2-year-old studies (gray circles). The best-ﬁtting regression models (see
Table 1) are shown as lines with the corresponding 95% confidence belt for the mean effect as dotted
lines, with colors of lines corresponding to colors of data. For E2, the range of EC05 values (EC05 = 3 × 10E–6
– 2.2 × 10E–4) is pictured, as obtained from data from different studies. 
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Figure 1. Concentration–response data and curves for estriol, coumesterol, and β-endosulfan. The best-
fitting regression models (see Table 1) are shown as blue lines with the corresponding 95% confidence
belt for the mean effect as dotted blue lines. Blue circles refer to the NOECs, derived by a nonparametric
contrast test.
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β-Endosulfan2002; Koppen et al. 2002; Link et al. 2005;
Raaschou-Nielsen et al. 2005). 
For those organochlorine pesticides with-
out sufficient available data (α-endosulfan,
endosulfan o,p´-DDD), conversion from
adipose tissue levels to serum levels and vice
versa was carried out as described by Lopez-
Cervantes et al. (2004).
For many of the chemicals tested in the
E-Screen, low-dose estimates were removed
by a factor of between 5 and 100 from the
highest measured levels in human serum.
However, there were notable exceptions: All
low-dose measures for bisphenol A and
o,p´-DDT fell near the median of serum lev-
els measured in Europe, and toward the high
end of serum levels, there were overlaps with
the estimates derived for dieldrin and
p,p´-DDT (Figure 3B). With adipose tissue
levels, the low-dose estimates for all chemicals
except dieldrin and aldrin covered the range
of measured values.
Discussion
The focus of most of the E-Screen studies car-
ried out with xenostrogens in the past was on
deﬁning potencies in relation to endogenous
hormones, and presumably for this reason,
information about low-dose effects is scarce.
Systematic attempts to titrate doses down into
the range at the ”threshold” between effect and
no-effect are missing. The experiments pre-
sented here were intended to ﬁll this gap and
enable us to draw the following conclusions:
Apart from a down-turn of responses near
the high end of tested concentrations,
inverted U-shapes in the range of low-effect
doses were generally not observed under our
experimental conditions, and this may be spe-
cific for the end point investigated in the
E-Screen. Instead, detailed low-dose–response
analyses revealed that many of the tested
agents exhibited quite shallow curves in the
low-effect range, and this resulted in low-dose
estimates with often surprisingly small
numerical values. In terms of small gradients,
high potency and correspondingly low-effect
dose estimates, the steroidal estrogens stood
out. It is remarkable that this feature was less
pronounced with all the synthetic xenoestro-
gens where low responses returned to control
levels far more rapidly as the doses decreased.
There are two possible reasons for the
observed slow leveling of effects observed with
E2. One hypothesis is that they are due to the
secretion of messenger substances via
autocrine or paracrine loops, which serve to
induce small proliferative responses at very
low concentrations. Hamelers et al. (2003)
have shown that E2-responsive MCF-7 cell
lines release a factor capable of activating the
insulin-like grown factor (IGF) receptor,
when treated with E2, and that this factor
synergizes with small concentrations of E2.
However, little information is available about
the concentration range of E2 effective in trig-
gering the release of such factors. The tran-
scription of other E2-inducible autocrine
factors such as transforming growth factor
(TGF)-α and stromal cell-derived factor-1
(SDF-1) is suppressed, not stimulated, by low
concentrations of E2 (Coser et al. 2003). An
alternative explanation for the shallow
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Table 3. Reference studies used for comparison between tissue levels in humans and E-Screen low-dose estimates. 
Adipose tissue Serum
Agent Lowest conc.a Reference Highest conc.a Reference Lowest conc.a Reference Highest conc.a Reference
Bisphenol Ab — — — — 0.3 ng/mLc Schönfelder et al. 18.9 ng/mLd Schönfelder 
(1.3 nM) 2002 (83 nM) et al. 2002
β-HCH 3.9e Pauwels et al.  1,670e Molina et al.  7.4c Weiderpass et al. 744d Weiderpass 
(12.2 nM) et al. 2000 (5,220 nM) 2005 (0.2 nM) 2000 (20 nM) et al. 2000
Methoxychlor 3.54e Fernández et al.  155.6d Botella et al.  0.84e,f Fernández et al. 0.38 ng/mLe Botella et al.
(9.3 nM) 2004 (409 nM) 2004 (0.02 nM) 2004 (1.1 nM) 2004
β-Endosulfan (II) 6.63e Cerrillo et al.  414.1d Botella et al.  1.58e,f Cerrillo et al. 35.92 ng/mLd Botella et al.
(14.8 nM) 2005 (925 nM) 2004 (0.03 nM) 2005 (88.3 nM) 2004
α-Endosulfan (I) 1.82e Fernández et al.  23.1d Botella et al.  0.43e,f Fernández et al.  7.27ng/mLd Botella et al.
(4.1 nM) 2004 (51.5 nM) 2004 (0.008.2 nM) 2004 (18 nM) 2004
Aldrin 10.5e Fernández et al.  137.2d Botella et al.  2.17 ng/mLe Botella et al. 372.9 ng/mLd Cruz et al. 
(26.2 nM) 2004 (342 nM) 2004 (5.95 nM) 2004 (1,022 nM) 2003
Dieldrin 6.52e Fernández et al.  84.05d Botella et al.  1.21 ng/mLe Botella et al. 356.4 ng/mLd Cruz et al. 
(15.5 nM) 2004 (40.6 nM) 2004 (3.17 nM) 2004 (935 nM) 2003
p,p´-DDT 11.0e Smeds and Saukko  2610e Molina et al.  4.0c Glynn et al. 814.9 ng/mLd Cruz et al. 
(28 nM) 2001 (6,693 nM) 2005 (0.087 nM) 2000 (2,299 nM) 2003
o,p´-DDD 28.7e,f Zumbado et al.  436.8e,f Zumbado et al.  6.83e Zumbado et al.  104e Zumbado 
(81 nM) 2005 (1,241 nM) 2005 (0.16 nM) 2005 (2.5 nM) et al. 2005
p,p´-DDE 38.0c Covaci et al.  15,574d Pavuk et al.  25.0c Glynn et al. 390.5 ng/mLd Cruz et al. 
(110 nM) 2002 (44,506 nM) 2004 (0.6 nM) 2000 (1,226 nM) 2003
o,p´-DDT 13.5e Botella et al.  57.1d Botella et al.  2.2e Glynn et al. 256.7 ng/mLd Cruz et al. 
(34 nM) 2004 (150 nM) 2004 (0.048 nM) 2000 (723 nM) 2003
conc, concentration.
aConcentrations are shown as units published in corresponding reference in ng/g lipid, unless stated otherwise (conversion to molar concentrations, calculated for this study).
bConcentrations of bisphenol A are in plasma. Values from publications are cminimum (above limit of detection), dmaximum, and emean. fConversion from adipose tissue concentration to
serum concentration and vice versa as described by Lopez-Cervantes et al.( 2004).
Figure 3. Comparison between human levels and E-Screen low-dose estimates for some tested xenoestro-
gens. White horizontal bars represent the range of concentrations of the tested chemicals present in
human adipose tissue (A) and serum (B), as reported on the publications listed in Table 3. Blue vertical lines
are the NOECs for each of the compounds. Black horizontal bars represent the range of low dose estimates
in the E-Screen, delimited on the left by EC01 values and on the right by EC05 values (black vertical lines). 
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101 102 103 104 10–1 10–2 10–3 10–4concentration–response curve of E2 may be
sought by invoking an inhibitory effect of the
hormone on apoptosis rather than to a prolif-
erative effect. A study by Hur and colleagues
(2004) has shown that low concentrations of
E2 block the transcription of Bik, a proapop-
totic protein, which is expressed in MCF-7
BOS cells in the absence of estrogens. 
It is striking that the dose–response
curves observed with xenoestrogens were
noticeably less shallow in the low-dose range.
We speculate that xenoestrogens may lack
the ability to induce signaling loops or anti-
apoptotic effects similar to E2, but experi-
mental evidence to support this suggestion is
lacking at present.
Dose–response curves with small gradi-
ents give rise to complications during the esti-
mation of low-effect doses. As illustrated by
our experiments with E2, high statistical
power is necessary to arrive at valid estimates,
and in this sense, the E-Screen serves as an
illustrative example for the resources that are
needed for the demonstration of effects with
small magnitudes. Through using large sam-
ple sizes and numerous repeats, the experi-
mental power of the E-Screen was sufﬁciently
high to measure effect magnitudes of around
1–2% with reliability. However, such
resources are usually not available for in vivo
testing, with the consequence that the statisti-
cal detection limit is often considerably
higher. If this coincides with shallow
dose–response curves in the low-effect range
(which is normally not measurable in vivo),
the limited resolving power of in vivo assays
may seriously constrain low-dose testing. This
aspect of the EDC low-dose issue has not
been appreciated sufﬁciently in the past.
In the examples presented here, the low-
dose estimates derived from hypothesis testing
agreed reasonably well with those obtained by
regression modeling. To a large extent, this was
because of our narrow spacing of tested con-
centrations in the low-dose range. Because
NOECs are deﬁned in relation to LOECs—
they are the next lower tested concentrations—
their numeric value depends heavily on the
choice of concentrations selected for testing.
With shallow gradients of the underlying
response curves, tight spacing will tend to yield
higher NOECs, and under such conditions
they are likely to be similar to regression-based
estimates such as EC01 or EC05, as in our case.
Depending on the experimental power and the
chemical tested, NOECs were close to the esti-
mated EC01 and thus associated with prolifera-
tive effects of around 1% (Table 2). The
resolving power of the E-Screen was not sufﬁ-
cient to say with certainty whether these con-
centrations provoked proliferative effects, nor
could such effects be ruled out with certainty
(as indicated by the model estimation). This is
in contrast with the widespread perception
of NOECs (and NOELs) as values that signal
complete absence of effects. When effect vari-
ation is high, and experimental power com-
paratively low, NOECs can be associated with
effect magnitudes as high as 10–20% (Moore
and Caux 1997), and this has led to sharp
criticism of thoughtless use of the terms
NOEL and NOEC [“one of the most misun-
derstood concepts in ecotoxicology” (Moore
and Caux 1997)].
The realization that even the statistical
power afforded by a high-throughput assay
such as the E-Screen is insufﬁcient to resolve
effect magnitudes smaller than 1% raises the
issue whether such small effects, although sta-
tistically relevant, also have biological mean-
ing. Thus, if it is difficult to derive a zero
effect level for xenoestrogens in the E-Screen,
would not a solution to this dilemma present
itself by deﬁning a proliferative effect of bio-
logical signiﬁcance that should be avoided to
protect the exposed organism? Concentrations
associated with such “critical” effect sizes
could then be used to derive better defined
quality standards. 
However, our knowledge about the role
of estrogens, both steroidal and man-made, in
the normal development of the breast as well
as in the induction of neoplasia is too frag-
mentary to provide conclusive answers to this
question. As yet, there is no consensus about
the way in which steroidal estrogens promote
cell division in the mammary gland [see dis-
cussions by Cheng et al. (2004); Clarke
(2003); Smalley and Ashworth (2003)].
According to one widely held view, estrogens
provide stimuli for the clonal expansion of
precancerous cell populations (Smalley and
Ashworth 2003). If this is true, then even
small proliferative effects, over decades, may
contribute to the clonal expansion of precan-
cerous cells. Viewed from such a long-term
perspective, any attempts to establish a critical
effect size below which risks are negligible
may be problematic. 
MCF-7 cells are used widely as a model to
represent estrogen-responsive breast cancer
cells (Spink et al. 2006), but it is unclear
whether their sensitivity to estrogens is repre-
sentative of the situation in vivo. Bearing this
proviso in mind, it may nevertheless be of
interest to compare E-Screen low-dose
estimates with the tissue levels determined in
European citizens. In making such compari-
sons, it is important to reflect on the dose
metric used as a basis. It is difﬁcult to deﬁne
the target doses of these chemicals received
locally by cells in the human mammary gland,
but regardless of this complication, blood
serum levels are often regarded as reasonable
measures of such internal exposure. Pointing
to the high levels of some xenoestrogens in
adipose tissue and the close proximity of
epithelial cells that line the milk ducts of the
female breast with the surrounding adipo-
cytes, Shekhar and colleagues (1997) have
argued that epithelial cells may be exposed to
higher levels of xenoestrogens than suggested
by serum levels. Although this may be the
case, it also appears plausible that xenoestro-
gens are more easily available to mammary
cells from blood serum, which would mean
that serum levels are a better measure of the
“dose at target.” Because a firm decision on
these matters cannot be reached at present
because of a lack of evidence, we decided to
take a pragmatic course and compare
E-Screen low-effect dose estimates with both
serum and adipose tissue levels.
Considering the 5- to 100-fold margin
between our E-Screen low-dose estimates and
the high end of the range of measured serum
levels, it appears unlikely that the majority of
the tested chemicals individually are able to
induce biologically significant degrees of cell
proliferation at these exposure levels. This con-
clusion needs to be tempered in view of the
likelihood of possible combination effects of
these chemicals (Rajapakse et al. 2004), but
this awaits experimental conﬁrmation. To our
surprise, this reasoning could not be extended
to bisphenol A and o,p´-DDT. In both these
cases, our low-dose estimates were placed in
the mid-range of measured serum levels. For
o,p´-DDT, the span of measured serum levels
became extended toward the high end because
of the high measured values in parts of the
Canary Islands and Portugal. The high levels of
o,p´-DDT and corresponding metabolites in
these countries were attributed to high con-
sumption of contaminated foods from Asia
and Latin America, where DDT is still in use
(Cruz et al. 2003; Zumbado et al. 2005).
When adipose tissue levels were chosen as the
basis for comparisons, all low-dose estimates
with the exception of dieldrin and aldrin fell
within the span of measured values in Europe.
With α-endosulfan, β-endosulfan, and
methoxychlor, the overlap was toward the high
end of adipose tissue concentrations. Notable
are β-HCH, p,p´-DDT, and p,p´-DDE, where
the mid-range of levels was shown to elicit low
effects in the E-Screen. The outcomes of the
comparisons with human tissue levels are not
biased because of inconsistent application of
low-dose estimation procedures.
By conducting extensive dose–response
analyses with high experimental power, we
were able to show that estimates of low-effect
doses for xenoestrogens overlapped with some
tissue levels found in humans. Investigations
of the toxicologic relevance of these observa-
tions require more urgency than perhaps
thought previously. The usefulness of human
biomonitoring, animal experiments, and
in vitro assays could be enhanced by efforts to
explore the relationships between target doses
in vivo and effective concentrations in vitro.
Silva et al.
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